Asset Dedication LLC Has $3.66 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Asset Dedication LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 15.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,593 shares of the company’s stock after selling 4,212 shares during the quarter. Asset Dedication LLC’s holdings in Johnson & Johnson were worth $3,661,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. CFM Wealth Partners LLC grew its position in Johnson & Johnson by 14.2% in the third quarter. CFM Wealth Partners LLC now owns 2,595 shares of the company’s stock valued at $411,000 after acquiring an additional 323 shares during the period. Braun Bostich & Associates Inc. grew its holdings in shares of Johnson & Johnson by 6.6% in the 3rd quarter. Braun Bostich & Associates Inc. now owns 7,777 shares of the company’s stock worth $1,260,000 after purchasing an additional 483 shares during the last quarter. Acorn Creek Capital LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $277,000. QV Investors Inc. lifted its holdings in Johnson & Johnson by 0.3% during the 3rd quarter. QV Investors Inc. now owns 97,370 shares of the company’s stock valued at $15,780,000 after purchasing an additional 260 shares during the last quarter. Finally, Regatta Capital Group LLC boosted its position in Johnson & Johnson by 7.5% in the third quarter. Regatta Capital Group LLC now owns 6,684 shares of the company’s stock valued at $1,083,000 after buying an additional 468 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on JNJ. Morgan Stanley increased their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. TD Securities lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Six investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $174.31.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.6 %

NYSE:JNJ opened at $164.14 on Wednesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The stock’s fifty day moving average price is $162.70 and its two-hundred day moving average price is $154.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a market cap of $395.02 billion, a P/E ratio of 10.23, a P/E/G ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.80 EPS. As a group, analysts expect that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.